Beyond the lab: screening

Dear readers,

Today’s drug screening methods predominantly rely on one or two types of data, limiting their ability to replicate the intricate nature of disease biology. However, the advent of advanced screening techniques capable of processing numerous data sources simultaneously has unearthed novel hits that have eluded us throughout the history of medicine. In this report, we bring insight from esteemed professionals in the field, that highlights the possibility of overlooked breakthrough therapies and the transformative impact of innovative screening methods.

Expert insights

• Dr Aaron Daugherty, Vice President of Discovery at Aria Pharmaceuticals
• Dr Greg Neely, University of Sydney
• Dr Tijmen Booij and Dr Christian Stirnimann, ETH Zurich
• Dr Denise Barrault, Director of Portfolio Management at Exscientia
• Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics

We explore the development of a bioluminescence resonance energy-transfer sensor capable of reporting changes in intracellular calcium concentrations during screening, exemplifying the fascinating intersection of biology and technology. We also relay the application of a high-throughput assay to screen for potential small molecule inhibitors of SARS-CoV-2 replication, underscoring the ongoing efforts to combat the global pandemic.

We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.

Thank you for your continued support.

Sincerely,

Taylor Mixides

Editor

Drug Target Review